<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02772965</url>
  </required_header>
  <id_info>
    <org_study_id>16-0476</org_study_id>
    <secondary_id>PCS-1406-18643</secondary_id>
    <secondary_id>1U19AR069525-01</secondary_id>
    <secondary_id>PCD-MTX-001</secondary_id>
    <nct_id>NCT02772965</nct_id>
  </id_info>
  <brief_title>Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy</brief_title>
  <acronym>COMBINE</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Pragmatic Clinical Trial To Evaluate The Effectiveness Of Low Dose Oral Methotrexate In Patients With Pediatric Crohn's Disease Initiating Anti-TNF Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ImproveCareNow (ICN)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Leona M. and Harry B. Helmsley Charitable Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Grifols Diagnostics Solutions, Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether adding low dose methotrexate to anti -TNF
      therapy is more effective than treatment with anti-TNF therapy alone in inducing and
      maintaining steroid-free remission for children with Crohn's Disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overall study duration: 4 years Multi-center study: up to 42 centers

      Number of subjects: 425 Duration of treatment for each subject: up to 156 weeks (3 years)

      The primary endpoint is time to treatment failure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>Continuous from randomization through week 156</time_frame>
    <description>Time from randomization to treatment failure defined as follows: Failure to achieve remission (SPCDAI &lt; 15) by the week 26 visit; If study initiated on steroids, failure to complete steroid taper by week 16; SPCDAI ≥ 15, attributed to active Crohn's disease, at two or more consecutive visits beyond the week 26 visit. Elevated SPCDAI (≥ 15) due to a non-IBD reason (i.e., infection, IBS, normal colonoscopy or other test of mucosal inflammation) does not count toward this outcome; Hospitalization for active Irritable Bowel Disease or abdominal surgery after week 25; Use of oral prednisone or prednisolone, enteral release budesonide, or intravenous (IV) methylprednisolone for over 10 weeks cumulatively, beyond week 16. (Not inclusive of steroids used as premed for anti-TNF administration or steroids used for conditions other than CD); or discontinuation of anti-TNF or study drug for lack of effectiveness or toxicity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean PROMIS (Patient Reported Outcome Measurement and Information System) Pain Interference T score by treatment arm</measure>
    <time_frame>Week 52 and 104 from randomization</time_frame>
    <description>T scores are a continuous variable. The mean in the general population is 50 (SD=10). Scores above 50 represent higher than average pain interference and scores below 50 represent lower than average pain interference. We will compare the mean of PROMIS Pain Interference T scores at week 52 and week 104 between the treatment groups. Minimal important differences (MIDs) for many PROMIS domains are in the range of 2 to 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean PROMIS (Patient Reported Outcome Measurement and Information System) Fatigue T score by treatment arm</measure>
    <time_frame>Week 52 and 104 from randomization</time_frame>
    <description>T scores are a continuous variable. The mean in the general population is 50 (SD=10). Scores above 50 represent higher than average fatigue and scores below 50 represent lower than average fatigue. We will compare the mean of PROMIS Fatigue T scores at week 52 and week 104 between the treatment groups. Minimal important differences (MIDs) for many PROMIS domains are in the range of 2 to 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with positive anti-TNF antibody status</measure>
    <time_frame>Between week 91 and week 104 from randomization</time_frame>
    <description>Proportion of patients with positive anti-TNF antibody status will be compared between the two treatment groups using the chi-squared test. The year two sample will be collected at a single time point between week 91 and week 104 from randomization. if a sample is not collected in the second year, the sample collected in the first year will be used (week 14).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">425</enrollment>
  <condition>Pediatric Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methotrexate (10, 12.5, or 15 mg), once weekly. Weight-based dosing. Ondansetron (4 mg), twice weekly, 1 hour prior to methotrexate dose and the morning after methotrexate dose.
Folic Acid (1 mg) daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for methotrexate, once weekly. Placebo for ondansetron, twice weekly, 1 hour prior to methotrexate placebo dose and the morning after methotrexate placebo dose.
Folic Acid (1 mg) daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Oral methotrexate (MTX): The weekly dose will be 15 mg for children ≥ 40kg, 12.5 mg for children 30 to &lt;40 kg, and 10 mg for children 20 to &lt;30 kg.
A twice per week, 4mg dose of ondansetron will be provided as pre-treatment to prevent nausea (study provider may opt-out of this component based on clinical judgement).
A 1 mg dose of folic acid per day will be provided. This will help to reduce the risk of side effects in the MTX group.
Drug kits will contain a 3 month supply of each medication. Refills will be provided every 3 months until week 156 unless there is a failure to induce and maintain remission, development of unacceptable toxicity, pregnancy in a female participant, or failure of the participant to attend scheduled study visits.</description>
    <arm_group_label>Methotrexate</arm_group_label>
    <other_name>Methotrexate Sodium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sugar pill (placebo)</intervention_name>
    <description>Placebo for methotrexate: The weekly dose will mimic that of methotrexate.
Placebo for ondansetron: The weekly dose will mimic that of ondansetron (study provider may opt-out of this component based on clinical judgement).
A 1 mg dose of folic acid per day will be provided to maintain blinding.
Drug kits will contain a 3 month supply of each medication. Refills will be provided every 3 months until week 156 unless there is a failure to induce and maintain remission, development of unacceptable toxicity, pregnancy in a female participant, or failure of the participant to attend scheduled study visits.</description>
    <arm_group_label>Sugar pill (placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pediatric Crohn's Disease (PCD) patients, &lt; 21 years of age, ≥20 kg, initiating
             anti-TNF therapy with infliximab or adalimumab (including biosimilars).

          -  Diagnosis of Crohn's Disease (CD) established confirmed by the treating clinician, and
             established by standard clinical criteria (radiography, endoscopy, histology).

          -  Ability to provide parental permission and child assent (where applicable), or adult
             consent for patients ages 18-20.

        Exclusion Criteria:

          -  Prior use of anti-TNF or other biological therapy for CD

          -  Lack of stable home address that study medications can be mailed to

          -  Anticipated short length of follow up at study center (plans for family to move,
             transition to adult GI (gastrointestinal) provider, etc.). Patients expected to leave
             practice &lt; 12 months from enrollment should not be enrolled.

          -  Concurrent pelvic or abdominal abscess. A recent history of abdominal or pelvic
             abscess, which is controlled, does not exclude the subject.

          -  Prior intra-abdominal surgery without a clinically significant relapse (i.e. patients
             starting on anti-TNF for post-op prophylaxis or for endoscopic recurrence only should
             not be included)

          -  Receipt of a live virus vaccine within the last 30 days

          -  Pregnancy, planning to become pregnant, or high risk of pregnancy as determined by the
             local investigator

          -  Breastfeeding

          -  Refusal to stay abstinent or utilize 2 forms of birth control while on study
             medication (for female patients)

          -  BMI &gt; 98% for gender and age

          -  Known previous or concurrent malignancy (other than that considered surgically cured,
             with no evidence for recurrence for 5 years). A recent history of basal cell or
             squamous cell carcinoma, which is considered surgically cured, does not exclude the
             subject.Those with a recent history of colonic adenoma or dysplastic lesions should be
             excluded.

          -  Known high alcohol consumption (more than seven drinks per week)

          -  Patients with serum albumin &lt; 2.5 g/dl

          -  Patients with white blood cell count (WBC) &lt; 3.0 x109th/L

          -  Patients with platelet count &lt; 100 x109th/L

          -  Patients with initial elevation of liver enzymes (AST or ALT) &gt; 1.5 times above normal
             limit

          -  Patients with known active infection with Clostridium difficile (C. difficile)
             (untreated infection based on clinician assessment does not apply to colonization or
             infection controlled with current or prior treatment.)

          -  Patients with pre-existing hepatic disease

          -  Patients with pre-existing renal dysfunction (creatinine &gt; 0.8 for children age&lt;10,
             creatinine &gt; 1.2 mg/dl for children age 10-18, and creatinine &gt; 1.5 mg/dl for adults
             age 18 years and older).

          -  Patients with a pre-existing chronic lung disease other than well controlled asthma

          -  Current treatment with one of the following drugs: Probenecid (Probalan), Acitretin
             (Soriatane), Streptozocin (Zanosar), Azathioprine (Imuran, Azasan), 6-mercaptopurine
             (Purinethol, Purixan)

          -  Other concerns about the patient/family's ability to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael D Kappelman, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael D Kappelman, MD</last_name>
    <phone>(919) 843-5908</phone>
    <email>michael_kappelman@med.unc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ann Firestine</last_name>
    <phone>(919) 966-0144</phone>
    <email>annfire@unc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Mosteller-Barnum</last_name>
      <phone>205-638-5843</phone>
      <email>lbarnum@peds.uab.edu</email>
    </contact>
    <investigator>
      <last_name>Traci Jester</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Children's Health</name>
      <address>
        <city>Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aditi Gupta</last_name>
      <phone>415-359-6946</phone>
      <email>agupta13@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Dorsey Bass</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale-New Haven Children's Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Tirloni</last_name>
      <phone>203-785-3319</phone>
      <email>alicia.tirloni@ynhh.org</email>
    </contact>
    <investigator>
      <last_name>Dinesh Pashankar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Health System - Wilmington</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Klipner</last_name>
      <phone>302-651-4088</phone>
      <email>kklipner@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Zarela Molle Rios, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Health System - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynnette Lee</last_name>
      <phone>904-697-2128</phone>
      <email>Lynnette.Lee@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Jill Dorsey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nicklaus Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anabel Rodriguez</last_name>
      <phone>786-624-3829</phone>
      <email>Anabel.Rodriguez@nicklaushealth.org</email>
    </contact>
    <investigator>
      <last_name>Lina Felipez-Marrero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Health System - Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Henry</last_name>
      <phone>407-567-6202</phone>
      <email>Shannon.Henry@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Pablo Palomo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta at Egleston/Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Emetulu</last_name>
      <phone>706-461-9777</phone>
      <email>holoyed@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Subra Kugathasan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta at Scottish Rite-GI Care for Kids</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mallory McFarren</last_name>
      <phone>312-227-4650</phone>
      <email>mmcfarren@luriechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Jennifer Strople, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Shelly</last_name>
      <phone>317-948-5858</phone>
      <email>kashelly@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Steve Steiner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Children's Hospital</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Lynton</last_name>
      <phone>319-353-8525</phone>
      <email>Jessica-lynton@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Dawn Ebach</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MassGeneral Hospital for Children</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hailee Reeves</last_name>
      <phone>781-622-0393</phone>
      <email>hreeves@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Jess Kaplan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bridget Carey</last_name>
      <phone>857-218-4979</phone>
      <email>Bridget.Carey@Childrens.Harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Athos Bousvaros, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan | CS Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ila Moncion</last_name>
      <phone>734-232-6270</phone>
      <email>ilajm@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Jeremy Adler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corey Schurman</last_name>
      <phone>816-302-0252</phone>
      <email>crschurman@cmh.edu</email>
    </contact>
    <investigator>
      <last_name>Julie Bass, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardinal Glennon Children's Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Light</last_name>
      <phone>314-268-2700</phone>
      <phone_ext>6145</phone_ext>
      <email>lightjk@slu.edu</email>
    </contact>
    <investigator>
      <last_name>Helen Pappa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Louis Children's Hospital | Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiawana Thompson</last_name>
      <phone>314-454-4486</phone>
      <email>thompson_t@kids.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Chip Samson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Medical Center Omaha</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kym Abraham</last_name>
      <phone>402-559-2977</phone>
      <email>kabraham@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Kusek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Kravis Children's Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Serphos</last_name>
      <phone>212-241-3531</phone>
      <email>danielle.serphos@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Keith Benkov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Upstate Golisano Children's Hospital</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Blystone</last_name>
      <phone>315-464-8468</phone>
      <email>BlystonL@upstate.edu</email>
    </contact>
    <investigator>
      <last_name>Prateek Wali</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Lewis</last_name>
      <phone>919-843-9547</phone>
      <email>mary_lewis@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Ajay Gulati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Levine Children's Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Shonce</last_name>
      <phone>704-607-3264</phone>
      <email>Ryan.Shonce@carolinashealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Tiffany Linville, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Lake</last_name>
      <phone>513-636-0572</phone>
      <email>Kathleen.Lake@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Phil Minar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies &amp; Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelsey Lesniak</last_name>
      <phone>216-286-9678</phone>
      <email>Kelsey.Lesniak2@UHhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Jonathan Moses</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ling Fan</last_name>
      <phone>614-722-3412</phone>
      <email>Ling.Fan@nationwidechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Brendan Boyle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dayton Children's Hospital</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leah Tackett</last_name>
      <phone>937-641-4467</phone>
      <email>TackettL@childrensdayton.org</email>
    </contact>
    <investigator>
      <last_name>Kelly Sandberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oklahoma University Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Redmond</last_name>
      <phone>513-803-8026</phone>
      <email>Kathy-Redmond@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>John Grunow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monroe Carell Jr. Children's Hospital at Vanderbilt</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chelsea Campbell</last_name>
      <phone>615-875-6039</phone>
      <email>chelsea.n.campbell@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Diana Riera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Vermont Children's Hospital</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian McHale</last_name>
      <phone>802-656-9094</phone>
      <email>ian.mchale@med.uvm.edu</email>
    </contact>
    <investigator>
      <last_name>Jillian Sullivan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pediatric Specialists of Virginia</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernadatte Diez</last_name>
      <phone>703-839-8710</phone>
      <email>BDIEZ@psvcare.org</email>
    </contact>
    <investigator>
      <last_name>Ian Leibowitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of The King's Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Quinn</last_name>
      <phone>757-668-7755</phone>
      <email>Amy.Quinn@chkd.org</email>
    </contact>
    <investigator>
      <last_name>Rana Ammoury</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephanie Lammers</last_name>
      <phone>206-987-1062</phone>
      <email>Stephanie.Lammers@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Lee Dale</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Unteutsch</last_name>
      <phone>414-266-4844</phone>
      <email>runteutsch@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Jose Cabrera</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 27, 2016</study_first_submitted>
  <study_first_submitted_qc>May 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2016</study_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

